ZA200801362B - Solid pharmaceutical dosage form - Google Patents

Solid pharmaceutical dosage form Download PDF

Info

Publication number: ZA200801362B
Authority: ZA; South Africa
Prior art keywords: dosage form; weight; solid; surfactant; water
Prior art date: 2003-08-28

Application number

ZA200801362A

Other languages

English (en)

Inventor

Rosenberg Joeerg

Reinhold Ulrich

Liepold Bernd

Berndl Gunther

Breitenbach Joerg

Alani Laman

Ghosh Soumojeet

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-28

Filing date

2004-08-23

Publication date

2009-03-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34217089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200801362(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-08-23 Application filed by Abbott Lab filed Critical Abbott Lab

2009-03-25 Publication of ZA200801362B publication Critical patent/ZA200801362B/en

Links

239000002552 dosage form Substances 0.000 title claims abstract description 67
239000007787 solid Substances 0.000 title claims abstract description 14
229920003169 water-soluble polymer Polymers 0.000 claims abstract description 19
239000007962 solid dispersion Substances 0.000 claims abstract description 11
-1 sorbitan fatty acid ester Chemical class 0.000 claims description 32
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 28
229920001577 copolymer Polymers 0.000 claims description 28
229960000311 ritonavir Drugs 0.000 claims description 28
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 28
239000004094 surface-active agent Substances 0.000 claims description 27
KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 21
229960004525 lopinavir Drugs 0.000 claims description 20
239000006104 solid solution Substances 0.000 claims description 17
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 13
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical group OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 12
235000014113 dietary fatty acids Nutrition 0.000 claims description 11
239000000194 fatty acid Substances 0.000 claims description 11
229930195729 fatty acid Natural products 0.000 claims description 11
239000000243 solution Substances 0.000 claims description 10
150000002148 esters Chemical class 0.000 claims description 9
229920000642 polymer Polymers 0.000 claims description 9
239000000654 additive Substances 0.000 claims description 8
229920001519 homopolymer Polymers 0.000 claims description 8
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 7
229920001531 copovidone Polymers 0.000 claims description 7
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims description 6
239000000314 lubricant Substances 0.000 claims description 6
235000011071 sorbitan monopalmitate Nutrition 0.000 claims description 6
239000001570 sorbitan monopalmitate Substances 0.000 claims description 6
229940031953 sorbitan monopalmitate Drugs 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 5
230000000996 additive effect Effects 0.000 claims description 5
239000007884 disintegrant Substances 0.000 claims description 5
239000011159 matrix material Substances 0.000 claims description 5
239000007909 solid dosage form Substances 0.000 claims description 5
229920002554 vinyl polymer Polymers 0.000 claims description 5
239000004067 bulking agent Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 2
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
208000031886 HIV Infections Diseases 0.000 claims 1
208000037357 HIV infectious disease Diseases 0.000 claims 1
240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
239000004030 hiv protease inhibitor Substances 0.000 abstract description 17
229940122440 HIV protease inhibitor Drugs 0.000 abstract description 10
108010010369 HIV Protease Proteins 0.000 abstract description 4
239000008180 pharmaceutical surfactant Substances 0.000 abstract description 4
239000003112 inhibitor Substances 0.000 abstract description 2
241000282472 Canis lupus familiaris Species 0.000 description 19
229920003171 Poly (ethylene oxide) Polymers 0.000 description 16
239000000203 mixture Substances 0.000 description 16
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
239000004480 active ingredient Substances 0.000 description 13
239000008187 granular material Substances 0.000 description 12
238000000034 method Methods 0.000 description 12
229940079593 drug Drugs 0.000 description 11
239000008119 colloidal silica Substances 0.000 description 9
239000000155 melt Substances 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
241000725303 Human immunodeficiency virus Species 0.000 description 8
239000000463 material Substances 0.000 description 7
150000001875 compounds Chemical class 0.000 description 5
230000036470 plasma concentration Effects 0.000 description 5
239000008389 polyethoxylated castor oil Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000011734 sodium Substances 0.000 description 5
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
241000700605 Viruses Species 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
229960000502 poloxamer Drugs 0.000 description 4
229920001983 poloxamer Polymers 0.000 description 4
229920000136 polysorbate Polymers 0.000 description 4
239000000047 product Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
208000030507 AIDS Diseases 0.000 description 3
PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
229920002556 Polyethylene Glycol 300 Polymers 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000011575 calcium Substances 0.000 description 3
239000000378 calcium silicate Substances 0.000 description 3
229910052918 calcium silicate Inorganic materials 0.000 description 3
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
239000000945 filler Substances 0.000 description 3
239000000178 monomer Substances 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
108091005502 Aspartic proteases Proteins 0.000 description 2
102000035101 Aspartic proteases Human genes 0.000 description 2
SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
108010076039 Polyproteins Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
235000004443 Ricinus communis Nutrition 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000000975 dye Substances 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
229920001903 high density polyethylene Polymers 0.000 description 2
239000004700 high-density polyethylene Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
239000004611 light stabiliser Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
235000020925 non fasting Nutrition 0.000 description 2
239000008184 oral solid dosage form Substances 0.000 description 2
229920000620 organic polymer Polymers 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
239000004014 plasticizer Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000002516 radical scavenger Substances 0.000 description 2
238000007493 shaping process Methods 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
229940035044 sorbitan monolaurate Drugs 0.000 description 2
235000011067 sorbitan monolaureate Nutrition 0.000 description 2
238000005507 spraying Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
239000004408 titanium dioxide Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000005303 weighing Methods 0.000 description 2
GFDFZTFQPIBNSQ-UHFFFAOYSA-N (+)-homo-18-epiormosanine Natural products C1C(C23)CCCN3CN3CCCCC3C32CN2CCCCC2C1C3 GFDFZTFQPIBNSQ-UHFFFAOYSA-N 0.000 description 1
SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 1
CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
101100042630 Caenorhabditis elegans sin-3 gene Proteins 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
229920005682 EO-PO block copolymer Polymers 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
241001539176 Hime Species 0.000 description 1
GFDFZTFQPIBNSQ-LDIYZUBKSA-N Homoormosanine Natural products N12[C@H]3[C@H](C[C@H]4[C@@H]5N(C[C@@]3([C@@H]3N(C1)CCCC3)C4)CCCC5)CCC2 GFDFZTFQPIBNSQ-LDIYZUBKSA-N 0.000 description 1
229930186657 Lat Natural products 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241000252067 Megalops atlanticus Species 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920002675 Polyoxyl Polymers 0.000 description 1
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
241000206607 Porphyra umbilicalis Species 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
241000700159 Rattus Species 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 1
HVVWZTWDBSEWIH-UHFFFAOYSA-N [2-(hydroxymethyl)-3-prop-2-enoyloxy-2-(prop-2-enoyloxymethyl)propyl] prop-2-enoate Chemical compound C=CC(=O)OCC(CO)(COC(=O)C=C)COC(=O)C=C HVVWZTWDBSEWIH-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
229960001830 amprenavir Drugs 0.000 description 1
YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000000987 azo dye Substances 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
235000001465 calcium Nutrition 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003245 coal Substances 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
238000002050 diffraction method Methods 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000007459 endoscopic retrograde cholangiopancreatography Methods 0.000 description 1
UIWXSTHGICQLQT-UHFFFAOYSA-N ethenyl propanoate Chemical compound CCC(=O)OC=C UIWXSTHGICQLQT-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229960003142 fosamprenavir Drugs 0.000 description 1
MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
230000009477 glass transition Effects 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
238000000227 grinding Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000001023 inorganic pigment Substances 0.000 description 1
239000000905 isomalt Substances 0.000 description 1
235000010439 isomalt Nutrition 0.000 description 1
HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
GFDFZTFQPIBNSQ-WSBLSWJJSA-N jamine Chemical compound C([C@H]([C@H]12)C3)CCN2CN2CCCC[C@@H]2[C@]21CN1CCCC[C@@H]1[C@H]3C2 GFDFZTFQPIBNSQ-WSBLSWJJSA-N 0.000 description 1
238000004898 kneading Methods 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000003202 long acting thyroid stimulator Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
125000005395 methacrylic acid group Chemical group 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
238000003801 milling Methods 0.000 description 1
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000012860 organic pigment Substances 0.000 description 1
235000011837 pasties Nutrition 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940094335 peg-200 dilaurate Drugs 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000005498 phthalate group Chemical class 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229920005606 polypropylene copolymer Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
229960001852 saquinavir Drugs 0.000 description 1
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
238000010008 shearing Methods 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
239000010959 steel Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229940032085 sucrose monolaurate Drugs 0.000 description 1
229940035023 sucrose monostearate Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000002076 thermal analysis method Methods 0.000 description 1
210000003371 toe Anatomy 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229940023080 viracept Drugs 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000001786 wide angle neutron scattering Methods 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA200801362A 2003-08-28 2004-08-23 Solid pharmaceutical dosage form ZA200801362B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10/650,178 US20050048112A1 (en)	2003-08-28	2003-08-28	Solid pharmaceutical dosage form

Publications (1)

Publication Number	Publication Date
ZA200801362B true ZA200801362B (en)	2009-03-25

Family

ID=34217089

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
ZA200801362A ZA200801362B (en)	2003-08-28	2004-08-23	Solid pharmaceutical dosage form
ZA200601718A ZA200601718B (en)	2003-08-28	2006-02-27	Solid pharmaceutical dosage form
ZA2008/01361A ZA200801361B (en)	2003-08-28	2008-02-08	Solid pharmaceutical dosage form

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
ZA200601718A ZA200601718B (en)	2003-08-28	2006-02-27	Solid pharmaceutical dosage form
ZA2008/01361A ZA200801361B (en)	2003-08-28	2008-02-08	Solid pharmaceutical dosage form

Country Status (31)

Country	Link
US (1)	US20050048112A1 (es)
EP (6)	EP2942051B1 (es)
JP (6)	JP4815348B2 (es)
KR (5)	KR101132602B1 (es)
CN (5)	CN102764244A (es)
AT (1)	ATE516017T1 (es)
AU (3)	AU2004283087C1 (es)
CA (2)	CA2536638C (es)
CR (3)	CR8256A (es)
CY (5)	CY1111981T1 (es)
DK (5)	DK2258345T3 (es)
EA (4)	EA020992B1 (es)
EC (1)	ECSP066397A (es)
ES (5)	ES2608720T3 (es)
HK (4)	HK1094766A1 (es)
HR (1)	HRP20110555T1 (es)
HU (3)	HUE038792T2 (es)
IL (3)	IL173939A (es)
ME (2)	MEP17608A (es)
MX (2)	MX358033B (es)
NO (3)	NO330282B1 (es)
NZ (2)	NZ579622A (es)
PL (5)	PL1663183T3 (es)
PT (5)	PT2258344E (es)
RS (2)	RS59969B1 (es)
SG (3)	SG145690A1 (es)
SI (5)	SI2258345T1 (es)
TW (1)	TWI342221B (es)
UA (1)	UA85564C2 (es)
WO (1)	WO2005039551A2 (es)
ZA (3)	ZA200801362B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1175205B1 (en) *	1999-11-12	2006-06-14	Abbott Laboratories	Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US8025899B2 (en) *	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
US8377952B2 (en) *	2003-08-28	2013-02-19	Abbott Laboratories	Solid pharmaceutical dosage formulation
US20050048112A1 (en)	2003-08-28	2005-03-03	Jorg Breitenbach	Solid pharmaceutical dosage form
AU2012202831B2 (en) *	2005-02-23	2015-01-22	Abbvie Inc.	A solid pharmaceutical dosage formulation
KR20070025070A (ko) *	2005-08-31	2007-03-08	주식회사 대웅제약	시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
ATE482690T1 (de) *	2005-12-14	2010-10-15	Hoffmann La Roche	Hcv-prodrug-formulierung
JP5231242B2 (ja) *	2005-12-14	2013-07-10	シプラ・リミテッド	ヌクレオチド及びヌクレオシド系逆転写酵素阻害剤（テノホビル及びラミブジン）を剤形の異なる部分に含む医薬組合せ
WO2007087188A2 (en) *	2006-01-20	2007-08-02	Merck & Co., Inc.	Taste-masked tablets and granules
EP1832281A1 (en) *	2006-03-10	2007-09-12	Abbott GmbH & Co. KG	Process for producing a solid dispersion of an active ingredient
EP1880715A1 (en) *	2006-07-19	2008-01-23	Abbott GmbH & Co. KG	Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
TW200815033A (en) *	2006-08-10	2008-04-01	Cipla Ltd	Antiretroviral solid oral composition
WO2008067164A2 (en)	2006-11-15	2008-06-05	Abbott Laboratories	Solid pharmaceutical dosage formulations
CN103435570B (zh)	2007-02-23	2015-06-10	吉里德科学公司	治疗剂的药代动力学特性调节剂
GT200800303A (es) *	2007-12-24	2009-09-18		Combinacion anti-retroviral
EP2257279B1 (en) *	2008-02-28	2016-08-17	AbbVie Inc.	Preparation of tablets
WO2009153654A1 (en) *	2008-06-17	2009-12-23	Aurobindo Pharma Limited	Solid dosage forms of antiretrovirals
ES2598178T5 (es) *	2008-10-07	2023-12-26	Kudos Pharm Ltd	Formulación farmacéutica 514
EP2391350A1 (en)	2008-12-18	2011-12-07	Ranbaxy Laboratories Limited	Atazanavir formulations
TW201043269A (en) *	2009-04-14	2010-12-16	Bristol Myers Squibb Co	Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TWI540132B (zh)	2009-06-08	2016-07-01	亞培公司	Ｂｃｌ-２族群抑制劑之口服醫藥劑型
WO2011013110A1 (en)	2009-07-31	2011-02-03	Ranbaxy Laboratories Limited	Unit dosage forms of hiv protease inhibitors
EP2279728A1 (en)	2009-07-31	2011-02-02	Ranbaxy Laboratories Limited	Solid dosage forms of HIV protease inhibitors
CA2821992A1 (en)	2010-10-01	2012-04-05	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
UA113500C2 (xx)	2010-10-29	2017-02-10		Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA2829186A1 (en) *	2011-03-07	2012-09-13	Bandi Parthasaradhi Reddy	Amorphous form of lopinavir and ritonavir mixture
US9096556B2 (en)	2011-05-27	2015-08-04	Hetero Research Foundation	Amorphous ritonavir co-precipitated
CA2844827A1 (en) *	2011-08-16	2013-02-21	Merck Sharp & Dohme Corp.	Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
EP2564832A1 (en)	2011-08-29	2013-03-06	Hexal AG	Solid dosage form of HIV protease inhibitors
KR101794032B1 (ko) *	2011-09-21	2017-11-07	(주)바이오시네틱스	나노입자 제조방법
WO2013131646A1 (en)	2012-03-07	2013-09-12	Ratiopharm Gmbh	Dosage form comprising lopinavir and ritonavir
HUE027829T2 (en)	2012-03-07	2016-11-28	Ratiopharm Gmbh	Dosage forms containing non-crystalline lopinavir and crystalline ritonavir
CN103655571B (zh) *	2012-09-11	2016-04-20	上海星泰医药科技有限公司	一种洛匹那韦和利托那韦复方高均匀度纳米共分散体及其制备方法
WO2014048783A1 (en)	2012-09-27	2014-04-03	Basf Se	A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
US9744240B2 (en)	2012-09-27	2017-08-29	Basf Se	Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
WO2014048782A1 (en)	2012-09-27	2014-04-03	Basf Se	A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
US9789063B2 (en)	2012-09-27	2017-10-17	Basf Se	Storage-stable dust-free homogeneous particulate formulation
RU2505286C1 (ru) *	2012-12-29	2014-01-27	Открытое Акционерное Общество "Фармасинтез"	Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2543322C1 (ru) *	2013-09-19	2015-02-27	Открытое Акционерное Общество "Фармасинтез"	Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2619840C1 (ru) *	2016-09-21	2017-05-18	Общество с ограниченной ответственностью "Изварино Фарма"	Фармацевтическая композиция для лечения ВИЧ-инфекции
RU2659693C1 (ru) *	2017-06-30	2018-07-03	Общество с ограниченной ответственностью "Изварино Фарма"	Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
US20190038754A1 (en) *	2017-08-07	2019-02-07	SE Tylose, USA, Inc.	Pharmaceutical composition in solid extruded form
US20190269662A1 (en) *	2018-03-02	2019-09-05	The University Of Liverpool	Solid compositions of actives, processes for preparing same and uses of such solid compositions
CN108186578A (zh) *	2018-03-27	2018-06-22	聊城大学	一种利托那韦固体分散体的制备方法
EP3569225A1 (en)	2018-05-18	2019-11-20	Pharmaceutical Oriented Services Ltd	Solid dispersion containing ritonavir
TWI799599B (zh) *	2019-06-06	2023-04-21	華納國際生物科技股份有限公司	醫藥或保健品自乳化固體分散組成物
CN114146061B (zh) *	2020-09-07	2023-06-30	歌礼生物科技（杭州）有限公司	包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
EP4255495A1 (en)	2020-12-03	2023-10-11	Battelle Memorial Institute	Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
WO2022216977A1 (en)	2021-04-07	2022-10-13	Batelle Memorial Institute	Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
CN113318076B (zh) *	2021-06-02	2022-09-23	聊城大学	一种兼具增溶及抑晶效果的利托那韦固体分散体及其制备方法
CN114557967B (zh) *	2022-03-17	2023-06-02	乐普制药科技有限公司	一种利托那韦固体分散体的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2525108B1 (fr)	1982-04-19	1989-05-12	Elan Corp Ltd	Medicaments a haut degre de solubilite et procede pour leur obtention
DE3830353A1 (de)	1988-09-07	1990-03-15	Basf Ag	Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5354866A (en) *	1989-05-23	1994-10-11	Abbott Laboratories	Retroviral protease inhibiting compounds
US5696270A (en) *	1989-05-23	1997-12-09	Abbott Laboratories	Intermediate for making retroviral protease inhibiting compounds
US5542206A (en)	1994-10-11	1996-08-06	Lisch; Albert	Lure and tackle stacking container
US5914332A (en) *	1995-12-13	1999-06-22	Abbott Laboratories	Retroviral protease inhibiting compounds
US6232333B1 (en) *	1996-11-21	2001-05-15	Abbott Laboratories	Pharmaceutical composition
US6027747A (en) *	1997-11-11	2000-02-22	Terracol; Didier	Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
DE19841244A1 (de) *	1998-09-09	2000-03-16	Knoll Ag	Verfahren und Vorrichtung zum Herstellen von Tabletten
DE60039379D1 (de)	1999-02-10	2008-08-21	Pfizer Prod Inc	Pharmazeutische feste Dispersionen
US20030104048A1 (en) *	1999-02-26	2003-06-05	Lipocine, Inc.	Pharmaceutical dosage forms for highly hydrophilic materials
DE19913606A1 (de)	1999-03-25	2000-09-28	Basf Ag	Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
DE19913692A1 (de)	1999-03-25	2000-09-28	Basf Ag	Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
ATE429224T1 (de)	1999-06-04	2009-05-15	Abbott Lab	Arzneizubereitungen enthaltend mindestens einen hiv preoteaseinhibitor
ATE286720T1 (de)	1999-11-12	2005-01-15	Abbott Lab	Pharmazeutische formulierungen auf basis fester dispersionen
EP1175205B1 (en) *	1999-11-12	2006-06-14	Abbott Laboratories	Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
MXPA03011922A (es)	2001-06-22	2004-03-26	Pfizer Prod Inc	Composiciones farmaceuticas que contienen un dispersion solida de un farmaco ligeramente soluble en una matriz y plimero mejorador de solubilidad.
DE60320940D1 (de) *	2002-02-01	2008-06-26	Pfizer Prod Inc	Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
DE10213242A1 (de)	2002-03-25	2003-10-16	Abbott Gmbh & Co Kg	Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren
DE10247037A1 (de) *	2002-10-09	2004-04-22	Abbott Gmbh & Co. Kg	Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
US20050048112A1 (en)	2003-08-28	2005-03-03	Jorg Breitenbach	Solid pharmaceutical dosage form
US8377952B2 (en)	2003-08-28	2013-02-19	Abbott Laboratories	Solid pharmaceutical dosage formulation
WO2008067164A2 (en)	2006-11-15	2008-06-05	Abbott Laboratories	Solid pharmaceutical dosage formulations

2003
- 2003-08-28 US US10/650,178 patent/US20050048112A1/en not_active Abandoned
2004
- 2004-08-23 ES ES10181264.2T patent/ES2608720T3/es not_active Expired - Lifetime
- 2004-08-23 CA CA2536638A patent/CA2536638C/en not_active Expired - Fee Related
- 2004-08-23 CN CN2012102597395A patent/CN102764244A/zh active Pending
- 2004-08-23 JP JP2006524782A patent/JP4815348B2/ja not_active Expired - Lifetime
- 2004-08-23 ES ES10181250T patent/ES2399810T3/es not_active Expired - Lifetime
- 2004-08-23 AT AT04816820T patent/ATE516017T1/de active
- 2004-08-23 PT PT101812501T patent/PT2258344E/pt unknown
- 2004-08-23 DK DK10181264.2T patent/DK2258345T3/en active
- 2004-08-23 PL PL04816820T patent/PL1663183T3/pl unknown
- 2004-08-23 DK DK10181250.1T patent/DK2258344T3/da active
- 2004-08-23 CA CA2689639A patent/CA2689639C/en not_active Expired - Fee Related
- 2004-08-23 DK DK15169378.5T patent/DK2942051T3/en active
- 2004-08-23 EA EA200900292A patent/EA020992B1/ru not_active IP Right Cessation
- 2004-08-23 PL PL10181264T patent/PL2258345T3/pl unknown
- 2004-08-23 CN CN200480024748XA patent/CN1901884B/zh not_active Ceased
- 2004-08-23 RS RS20181262A patent/RS59969B1/sr unknown
- 2004-08-23 ME MEP-176/08A patent/MEP17608A/xx unknown
- 2004-08-23 CN CN201510531654.1A patent/CN105106104A/zh active Pending
- 2004-08-23 EP EP15169378.5A patent/EP2942051B1/en not_active Revoked
- 2004-08-23 MX MX2010013145A patent/MX358033B/es unknown
- 2004-08-23 CN CN201210259721.5A patent/CN102772380B/zh not_active Ceased
- 2004-08-23 UA UAA200603276A patent/UA85564C2/ru unknown
- 2004-08-23 SG SG200805563-4A patent/SG145690A1/en unknown
- 2004-08-23 RS YU20060140A patent/RS57663B1/sr unknown
- 2004-08-23 PL PL15169378T patent/PL2942051T3/pl unknown
- 2004-08-23 EA EA201301045A patent/EA033224B1/ru not_active IP Right Cessation
- 2004-08-23 ZA ZA200801362A patent/ZA200801362B/en unknown
- 2004-08-23 EP EP10181264.2A patent/EP2258345B1/en not_active Revoked
- 2004-08-23 KR KR1020067004057A patent/KR101132602B1/ko active IP Right Grant
- 2004-08-23 AU AU2004283087A patent/AU2004283087C1/en not_active Revoked
- 2004-08-23 PT PT04816820T patent/PT1663183E/pt unknown
- 2004-08-23 NZ NZ579622A patent/NZ579622A/en not_active IP Right Cessation
- 2004-08-23 NZ NZ545499A patent/NZ545499A/en not_active IP Right Cessation
- 2004-08-23 SG SG10201507902UA patent/SG10201507902UA/en unknown
- 2004-08-23 DK DK04816820.7T patent/DK1663183T3/da active
- 2004-08-23 SI SI200432367A patent/SI2258345T1/sl unknown
- 2004-08-23 EP EP17210362.4A patent/EP3354261A1/en not_active Withdrawn
- 2004-08-23 PL PL10181268T patent/PL2258346T3/pl unknown
- 2004-08-23 EP EP04816820A patent/EP1663183B9/en not_active Revoked
- 2004-08-23 PT PT101812642T patent/PT2258345T/pt unknown
- 2004-08-23 ES ES15169378.5T patent/ES2666390T3/es not_active Expired - Lifetime
- 2004-08-23 SI SI200431996T patent/SI2258344T1/sl unknown
- 2004-08-23 HU HUE15169378A patent/HUE038792T2/hu unknown
- 2004-08-23 EP EP10181268.3A patent/EP2258346B1/en not_active Revoked
- 2004-08-23 ES ES04816820T patent/ES2367173T3/es not_active Expired - Lifetime
- 2004-08-23 EP EP10181250A patent/EP2258344B1/en not_active Revoked
- 2004-08-23 KR KR1020127011945A patent/KR101457967B1/ko active IP Right Grant
- 2004-08-23 DK DK10181268.3T patent/DK2258346T3/da active
- 2004-08-23 EA EA200600473A patent/EA011924B1/ru not_active IP Right Cessation
- 2004-08-23 PL PL10181250T patent/PL2258344T3/pl unknown
- 2004-08-23 KR KR20157009392A patent/KR20150044031A/ko not_active Application Discontinuation
- 2004-08-23 WO PCT/US2004/027401 patent/WO2005039551A2/en active Application Filing
- 2004-08-23 ES ES10181268.3T patent/ES2653762T3/es not_active Expired - Lifetime
- 2004-08-23 KR KR1020147007592A patent/KR101563222B1/ko active IP Right Grant
- 2004-08-23 PT PT151693785T patent/PT2942051T/pt unknown
- 2004-08-23 SI SI200432438T patent/SI2942051T1/en unknown
- 2004-08-23 MX MXPA06002346A patent/MXPA06002346A/es active IP Right Grant
- 2004-08-23 ME MEP-2008-176A patent/ME00130B/me unknown
- 2004-08-23 PT PT101812683T patent/PT2258346T/pt unknown
- 2004-08-23 SI SI200431719T patent/SI1663183T1/sl unknown
- 2004-08-23 SI SI200432412T patent/SI2258346T1/sl unknown
- 2004-08-23 HU HUE10181264A patent/HUE031153T2/en unknown
- 2004-08-23 KR KR1020117025014A patent/KR101281994B1/ko active IP Right Grant
- 2004-08-23 SG SG2012008959A patent/SG179401A1/en unknown
- 2004-08-23 HU HUE10181268A patent/HUE035985T2/hu unknown
- 2004-08-23 EA EA201890737A patent/EA201890737A3/ru unknown
- 2004-08-23 CN CN2010102227346A patent/CN101919858B/zh not_active Ceased
- 2004-08-27 TW TW093125927A patent/TWI342221B/zh active
2006
- 2006-02-23 CR CR8256A patent/CR8256A/es unknown
- 2006-02-24 EC EC2006006397A patent/ECSP066397A/es unknown
- 2006-02-26 IL IL173939A patent/IL173939A/en active IP Right Grant
- 2006-02-27 ZA ZA200601718A patent/ZA200601718B/xx unknown
- 2006-03-24 NO NO20061342A patent/NO330282B1/no not_active Application Discontinuation
- 2006-12-06 HK HK06113444.9A patent/HK1094766A1/xx not_active IP Right Cessation
2007
- 2007-12-19 AU AU2007249115A patent/AU2007249115B2/en not_active Revoked
2008
- 2008-02-08 ZA ZA2008/01361A patent/ZA200801361B/en unknown
2010
- 2010-03-15 NO NO20100367A patent/NO334418B1/no not_active Application Discontinuation
- 2010-07-27 IL IL207260A patent/IL207260A/en active IP Right Grant
- 2010-11-01 AU AU2010238573A patent/AU2010238573B2/en not_active Revoked
- 2010-12-30 HK HK10112283.9A patent/HK1145969A1/xx not_active IP Right Cessation
2011
- 2011-02-18 JP JP2011032972A patent/JP5498411B2/ja not_active Expired - Lifetime
- 2011-07-06 JP JP2011149721A patent/JP5395125B2/ja not_active Expired - Lifetime
- 2011-07-25 HR HR20110555T patent/HRP20110555T1/hr unknown
- 2011-09-22 CY CY20111100923T patent/CY1111981T1/el unknown
2012
- 2012-12-21 CR CR20120661A patent/CR20120661A/es unknown
- 2012-12-21 CR CR20120662A patent/CR20120662A/es unknown
2013
- 2013-02-01 CY CY20131100093T patent/CY1113596T1/el unknown
- 2013-08-13 JP JP2013168001A patent/JP5903413B2/ja not_active Expired - Lifetime
- 2013-12-27 NO NO20131743A patent/NO335326B1/no not_active Application Discontinuation
2015
- 2015-12-04 JP JP2015237449A patent/JP2016094433A/ja not_active Withdrawn
2016
- 2016-05-10 HK HK16105307.9A patent/HK1217298A1/zh not_active IP Right Cessation
- 2016-12-19 CY CY20161101315T patent/CY1118505T1/el unknown
2017
- 2017-09-11 JP JP2017173733A patent/JP2018035163A/ja active Pending
- 2017-09-18 IL IL254581A patent/IL254581A0/en unknown
- 2017-11-03 CY CY20171101155T patent/CY1119651T1/el unknown
2018
- 2018-04-17 CY CY20181100407T patent/CY1120138T1/el unknown
- 2018-12-19 HK HK18116294.9A patent/HK1257502A1/zh unknown

Also Published As

Publication number	Publication date
HUE035985T2 (hu)	2018-06-28
NO330282B1 (no)	2011-03-21
ATE516017T1 (de)	2011-07-15
HK1094766A1 (en)	2007-04-13
JP2016094433A (ja)	2016-05-26
PL2258345T3 (pl)	2017-03-31
SG10201507902UA (en)	2015-10-29
JP4815348B2 (ja)	2011-11-16
JP5395125B2 (ja)	2014-01-22
EP2258344A2 (en)	2010-12-08
EA020992B1 (ru)	2015-03-31
AU2010238573B2 (en)	2012-12-13
AU2007249115B2 (en)	2010-08-12
PL2258346T3 (pl)	2018-01-31
CR20120662A (es)	2013-03-13
CN101919858A (zh)	2010-12-22
NO334418B1 (no)	2014-03-03
KR101457967B1 (ko)	2014-11-07
CN102772380B (zh)	2015-08-19
PT2942051T (pt)	2018-04-23
EP2942051A1 (en)	2015-11-11
HK1217298A1 (zh)	2017-01-06
CN102764244A (zh)	2012-11-07
RS20060140A (en)	2008-09-29
EA033224B1 (ru)	2019-09-30
CN1901884B (zh)	2012-07-25
DK2258346T3 (da)	2017-11-13
ECSP066397A (es)	2006-08-30
KR20110122771A (ko)	2011-11-10
KR101132602B1 (ko)	2012-04-06
JP2013241460A (ja)	2013-12-05
ZA200801361B (en)	2011-11-30
HRP20110555T1 (hr)	2011-09-30
CY1111981T1 (el)	2015-11-04
EA200900292A1 (ru)	2009-06-30
EP2258345B1 (en)	2016-09-21
RS59969B1 (sr)	2020-03-31
KR20120054666A (ko)	2012-05-30
MXPA06002346A (es)	2006-05-19
HUE038792T2 (hu)	2018-11-28
CY1120138T1 (el)	2018-12-12
SI2258346T1 (sl)	2017-12-29
MEP17608A (en)	2010-06-10
CA2536638C (en)	2010-04-06
EP1663183B1 (en)	2011-07-13
UA85564C2 (ru)	2009-02-10
CY1113596T1 (el)	2016-06-22
EP2258345A2 (en)	2010-12-08
CA2689639C (en)	2014-06-10
ES2653762T3 (es)	2018-02-08
NZ579622A (en)	2011-01-28
KR101281994B1 (ko)	2013-07-04
EP3354261A1 (en)	2018-08-01
EP1663183A2 (en)	2006-06-07
EA011924B1 (ru)	2009-06-30
EP1663183B9 (en)	2012-06-13
HK1145969A1 (en)	2011-05-13
EA201890737A2 (ru)	2018-08-31
DK2942051T3 (en)	2018-05-07
PT2258344E (pt)	2013-02-18
PL2942051T3 (pl)	2018-07-31
SI2942051T1 (en)	2018-06-29
JP2011236232A (ja)	2011-11-24
DK1663183T3 (da)	2011-08-29
PT1663183E (pt)	2011-08-25
SI2258344T1 (sl)	2013-03-29
KR20150044031A (ko)	2015-04-23
CR8256A (es)	2008-01-11
EP2258346B1 (en)	2017-09-27
EP2942051B1 (en)	2018-01-17
KR101563222B1 (ko)	2015-10-26
PT2258346T (pt)	2017-10-24
WO2005039551A2 (en)	2005-05-06
AU2004283087C1 (en)	2008-04-24
JP2011126898A (ja)	2011-06-30
CA2536638A1 (en)	2005-05-06
IL254581A0 (en)	2017-11-30
JP2007504142A (ja)	2007-03-01
CR20120661A (es)	2013-03-13
MX358033B (es)	2018-08-02
SI1663183T1 (sl)	2011-09-30
TW200522979A (en)	2005-07-16
DK2258345T3 (en)	2017-01-16
RS20181262A1 (sr)	2019-02-28
CN105106104A (zh)	2015-12-02
CY1119651T1 (el)	2018-04-04
AU2007249115A1 (en)	2008-01-10
CN1901884A (zh)	2007-01-24
SI2258345T1 (sl)	2017-01-31
IL173939A0 (en)	2006-07-05
AU2010238573A1 (en)	2010-11-18
EP2258344B1 (en)	2012-11-14
NO335326B1 (no)	2014-11-10
NO20061342L (no)	2006-05-29
EA200600473A1 (ru)	2006-10-27
KR20140046078A (ko)	2014-04-17
AU2004283087A1 (en)	2005-05-06
ES2399810T3 (es)	2013-04-03
JP5498411B2 (ja)	2014-05-21
WO2005039551A3 (en)	2006-08-03
PL1663183T3 (pl)	2011-10-31
NZ545499A (en)	2009-11-27
AU2004283087B2 (en)	2007-09-20
EP2258346A2 (en)	2010-12-08
ES2367173T3 (es)	2011-10-31
CA2689639A1 (en)	2005-05-06
CN102772380A (zh)	2012-11-14
NO20100367L (no)	2006-05-29
EA201301045A1 (ru)	2014-05-30
RS57663B1 (sr)	2018-11-30
EA201890737A3 (ru)	2019-01-31
ME00130B (me)	2010-10-10
DK2258344T3 (da)	2013-01-02
ES2666390T3 (es)	2018-05-04
ES2608720T3 (es)	2017-04-12
PT2258345T (pt)	2017-01-20
NO20131743L (no)	2006-05-29
EP2258346A3 (en)	2011-01-19
TWI342221B (en)	2011-05-21
SG179401A1 (en)	2012-04-27
JP2018035163A (ja)	2018-03-08
CN101919858B (zh)	2013-10-30
ZA200601718B (en)	2009-11-25
KR20060121837A (ko)	2006-11-29
IL207260A (en)	2017-10-31
SG145690A1 (en)	2008-09-29
EP2258344A3 (en)	2011-01-19
CY1118505T1 (el)	2017-07-12
HK1257502A1 (zh)	2019-10-25
PL2258344T3 (pl)	2013-04-30
EP2258345A3 (en)	2011-01-19
HUE031153T2 (en)	2017-07-28
US20050048112A1 (en)	2005-03-03
IL173939A (en)	2017-03-30
JP5903413B2 (ja)	2016-04-13

Publication	Publication Date	Title
ZA200801362B (en)	2009-03-25	Solid pharmaceutical dosage form
US8333990B2 (en)	2012-12-18	Solid pharmaceutical dosage form
KR101429024B1 (ko)	2014-08-12	약제학적 고체 투약 제형
AU2012202831B2 (en)	2015-01-22	A solid pharmaceutical dosage formulation
AU2013201423B2 (en)	2015-11-05	Solid pharmaceutical dosage form